Cartesian Therapeutics (RNAC) & Its Rivals Head to Head Comparison

Cartesian Therapeutics (NASDAQ:RNAC) is one of 1,060 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Cartesian Therapeutics to similar companies based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, risk, profitability and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cartesian Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	8	0	2.80
Cartesian Therapeutics Competitors	7751	21152	48865	1228	2.55

Cartesian Therapeutics currently has a consensus target price of $42.86, indicating a potential upside of 126.40%. As a group, “Pharmaceutical preparations” companies have a potential upside of 190.22%. Given Cartesian Therapeutics’ competitors higher probable upside, analysts clearly believe Cartesian Therapeutics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Cartesian Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cartesian Therapeutics	$47.94 million	-$219.71 million	-0.36
Cartesian Therapeutics Competitors	$9.59 billion	$147.39 million	-5.29

Cartesian Therapeutics’ competitors have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cartesian Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Cartesian Therapeutics Competitors	-3,590.11%	-276.96%	-39.10%

Risk and Volatility

Cartesian Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ competitors have a beta of 3.71, indicating that their average share price is 271% more volatile than the S&P 500.

Summary

Cartesian Therapeutics beats its competitors on 8 of the 13 factors compared.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.